Showing 6301-6310 of 6775 results for "".
- Research: Slow-release Nitric Oxide Particles May Reduce Inflammatory Acnehttps://practicaldermatology.com/news/research-slow-release-nitric-oxide-particles-may-reduce-inflammatory-acne/2458910/GW researcher and dermatologist, Adam Friedman, M.D., and colleagues, find that the release of nitric oxide over time may be a new way to treat and prevent acne through nanotechnology. This research, published in the Journal of Investigative Dermatology, identified that the nanoparticles were eff
- LEO Pharma Inc. Announces New Vice President of Saleshttps://practicaldermatology.com/news/leo-pharma-inc-announces-new-vice-president-of-sales/2458915/Mitchell Johnson has joined the LEO U.S. Region as Vice President of Sales. "Mitch is a welcomed addition to our team. He is an energetic sales leader and strategist with proven results in the pharmaceutical industry," stated Barbara Osborne, President & CEO, LEO U.S. Mr. Jo
- DermatologistOnCall Launches New Mobile Apphttps://practicaldermatology.com/news/dermatologistoncall-launches-new-mobile-app/2458919/DermatologistOnCall launched a new mobile app that it says enables patients to quickly and easily start and complete an online visit with a board-certified dermatologist. The app is free and works with Apple's iPhones and iPads, and Android phones and tablets. "Our new mobile app
- David Dobrowski Named Vice President, Head of North American Research and Development at Merzhttps://practicaldermatology.com/news/david-dobrowski-named-vice-president-head-of-north-american-research-and-development-at-merz/2458921/Merz North American appointed David Dobrowski Vice President and Head of North American Research and Development, effective immediately. In this role, Mr. Dobrowski is responsible for all medical, regulatory, and product safety functions for Merz in North America. He leads the planning and execut
- National Psoriasis Foundation Awards Half a Million Dollars in Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-half-a-million-dollars-in-fellowships/2458922/Eleven early-career physicians each received a one-year, $50,000 National Psoriasis Foundation Medical Dermatology Fellowship to study psoriasis and psoriatic arthritis. These fellowships will help increase the number of scientists studying
- Research Identifies Gene Linked to Melanoma Growth, Worse Outcomeshttps://practicaldermatology.com/news/research-identify-gene-linked-to-melanoma-growth-worse-outcomes/2458925/High levels of a specific protein linked to gene expression are associated with worse outcomes in melanoma, according to a study led by researchers at Icahn School of Medicine at Mount Sinai and published online in the journal Molecular Cell. Research shows that the protein, called H2A.Z.
- BTL Vanquish FDA Cleared for Circumferential Reduction of Abdomen Areahttps://practicaldermatology.com/news/btl-vanquish-fda-cleared-for-circumferential-reduction-of-abdomen-area/2458926/BTL Industries received FDA clearance of its BTL Vanquish device for circumferential reduction of the abdomen area. BTL Vanquish uses a panel array that emits selective RF energy with the largest spot size in the industry t
- Allergan to Acquire Kytherahttps://practicaldermatology.com/news/allergan-to-acquire-kythera/2458927/Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aestheti
- Neutrogena Sunscreens Awarded NEA Seal of Acceptancehttps://practicaldermatology.com/news/neutrogena-sunscreens-awarded-nea-seal-of-acceptance/2458928/The National Eczema Association (NEA) awarded its Seal of Acceptance to five Neutrogena sunscreens. This recognition is given to product innovations that help improve the quality of life for people with eczema, empowering consumers to make informed eczema purchase decisions. The fol
- FDA Grants Breakthrough Therapy Designation for Actemra in Systemic Sclerosishttps://practicaldermatology.com/news/fda-grants-breakthrough-therapy-designation-for-actemra-in-systemic-sclerosis/2458929/Genentech, a member of the Roche Group, was granted FDA Breakthrough Therapy Designation status for Actemra® (tocilizumab) for systemic sclerosis, also known as scleroderma. This designation is intended to expedite the development and review of medicines with early signals of poten